Nanoform Finland Oyj
OMXH:NANOFH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.1
3.1
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NANOFH stock under the Base Case scenario is 0.761 EUR. Compared to the current market price of 1.128 EUR, Nanoform Finland Oyj is Overvalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Nanoform Finland Oyj
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NANOFH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Nanoform Finland Oyj
Balance Sheet Decomposition
Nanoform Finland Oyj
Current Assets | 43.8m |
Cash & Short-Term Investments | 41.3m |
Receivables | 1m |
Other Current Assets | 1.4m |
Non-Current Assets | 28.5m |
Long-Term Investments | 1.3m |
PP&E | 26.4m |
Intangibles | 622k |
Other Non-Current Assets | 288k |
Current Liabilities | 6.6m |
Accounts Payable | 2m |
Accrued Liabilities | 2.6m |
Other Current Liabilities | 2.1m |
Non-Current Liabilities | 5m |
Long-Term Debt | 5m |
Other Non-Current Liabilities | -1k |
Earnings Waterfall
Nanoform Finland Oyj
Revenue
|
2.4m
EUR
|
Cost of Revenue
|
-16.4m
EUR
|
Gross Profit
|
-14m
EUR
|
Operating Expenses
|
-9.9m
EUR
|
Operating Income
|
-23.9m
EUR
|
Other Expenses
|
619.7k
EUR
|
Net Income
|
-23.2m
EUR
|
Free Cash Flow Analysis
Nanoform Finland Oyj
EUR | |
Free Cash Flow | EUR |
In a positive earnings call, Nanoform reported increased customer signings and strengthened relationships with major pharmaceutical companies, including Takeda. The company has made significant strides in its nanoenzalutamide and nanoapalutamide projects, projecting the first Nanoformed medicine to market by 2027 in the EU and 2028 in the USA. Nanoform expects revenue growth in the second half of the year due to increased project signings and in-sourcing of GMP QC to improve margins. The company maintains a strong balance sheet with over EUR 50 million in cash and no debt.
What is Earnings Call?
NANOFH Profitability Score
Profitability Due Diligence
Nanoform Finland Oyj's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
Score
Nanoform Finland Oyj's profitability score is 22/100. The higher the profitability score, the more profitable the company is.
NANOFH Solvency Score
Solvency Due Diligence
Nanoform Finland Oyj's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Nanoform Finland Oyj's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NANOFH Price Targets Summary
Nanoform Finland Oyj
According to Wall Street analysts, the average 1-year price target for NANOFH is 3.74 EUR with a low forecast of 3.03 EUR and a high forecast of 4.2 EUR.
Dividends
Current shareholder yield for NANOFH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Nanoform Finland Oyj engages in providing expert services in nanotechnology and drug particle engineering for the international pharma industry. The company is headquartered in Helsinki, Etela-Suomen and currently employs 158 full-time employees. The company went IPO on 2020-06-04. The firm is an early-stage growth Company that develops various nanoforming technologies for application in the field of nanomedicine. Nanoform Finland Oyj’s business is to offer expert services in nanotechnology as well as drug particle engineering for global pharma and biotech industry. Nanoform Finland Oyj is the Parent Company of the Nanoform Group, and it has one subsidiary - Nanoform USA Inc. The Group production, research and development functions operate in Finland. The Group’s strategy is to sell nanotechnological services widely to minimize the dependence from single customers or projects.
Contact
IPO
Employees
Officers
The intrinsic value of one NANOFH stock under the Base Case scenario is 0.761 EUR.
Compared to the current market price of 1.128 EUR, Nanoform Finland Oyj is Overvalued by 33%.